Cytospire Therapeutics
UKEntry
2026
Hold
New
Status
Active
Who owns Cytospire Therapeutics?
Cytospire Therapeutics is a British Biotech company, currently owned by Abingworth since 2026 and 2 other investors.
Hand-verified · updated 2026-05-21
Open JSON · CC-BY
Most recent investor
4Bio Partners4BIO Ventures III · 2022 · Life Sciences VC
3 ownership periods · full history below
Key facts
Ownership history
3 ownership periods
Active
LifeArcActive
2023 · present(3yr) · LifeArc Ventures · 1992 · Life Sciences VC
AbingworthActive
2026 · present(<1yr) · Abingworth Bioventures 8 · 2021 · Life Sciences VC
4Bio PartnersActive
2026 · present(<1yr) · 4BIO Ventures III · 2022 · Life Sciences VC
More from 4BIO Ventures III
Other portfolio companies in the same fund.
Italy
United States
Switzerland
More PE-backed in Biotech
Comparable biotech deals from other GPs.
Questions
Who owns Cytospire Therapeutics?
Cytospire Therapeutics is currently owned by Abingworth, 4Bio Partners and 1 other, through 4BIO Ventures III, since 2026.
When did Abingworth and 2 others acquire Cytospire Therapeutics?
Abingworth and 2 others acquired Cytospire Therapeutics in 2026.
Who has owned Cytospire Therapeutics over time?
Cytospire Therapeutics has been through 3 private-equity ownership periods: LifeArc · via LifeArc Ventures · since 2023; Abingworth · via Abingworth Bioventures 8 · since 2026; 4Bio Partners · via 4BIO Ventures III · since 2026.
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue